Trial Profile
A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs Glycopyrrolate (Primary) ; Olodaterol/tiotropium bromide (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 01 Jul 2022 Primary endpoint has not been met. (Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 4 hours (AUC0-4), as per Results published in the Journal of Asthma
- 01 Jul 2022 Results published in the Journal of Asthma
- 05 Nov 2019 Status changed from active, no longer recruiting to completed.